Notably, the phase III CAPItello-281 trial (NCT04493853) is assessing another AKT inhibitor (capivasertib) in combination with AR inhibition (GnRH agonist plus abiraterone and prednisone) in men with PTEN-deficient metastatic castration-sensitive PCa. This evidence concerns the gene AKT1 and posterior cortical atrophy.